Bio-Rad Laboratories, Inc. (NYSE:BIO) saw a significant increase in short interest in the month of August. As of August 31st, there was short interest totalling 552,800 shares, an increase of 14.7% from the July 31st total of 482,100 shares. Based on an average trading volume of 181,400 shares, the days-to-cover ratio is currently 3.0 days. Currently, 2.6% of the shares of the company are short sold.

In other Bio-Rad Laboratories news, EVP Michael Crowley sold 1,089 shares of the company’s stock in a transaction dated Wednesday, September 4th. The stock was sold at an average price of $333.08, for a total value of $362,724.12. Following the completion of the sale, the executive vice president now owns 2,011 shares in the company, valued at $669,823.88. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, EVP John Hertia sold 5,195 shares of the company’s stock in a transaction dated Friday, September 6th. The stock was sold at an average price of $336.57, for a total value of $1,748,481.15. Following the completion of the sale, the executive vice president now owns 15,507 shares of the company’s stock, valued at approximately $5,219,190.99. The disclosure for this sale can be found here. In the last three months, insiders sold 7,876 shares of company stock worth $2,634,905. 27.84% of the stock is owned by corporate insiders.

Several large investors have recently bought and sold shares of BIO. Motco bought a new stake in shares of Bio-Rad Laboratories in the 2nd quarter valued at approximately $25,000. Berman Capital Advisors LLC bought a new stake in shares of Bio-Rad Laboratories in the 2nd quarter valued at approximately $26,000. Capital Investment Advisory Services LLC bought a new stake in shares of Bio-Rad Laboratories in the 2nd quarter valued at approximately $48,000. Advisory Services Network LLC lifted its stake in shares of Bio-Rad Laboratories by 64.9% in the 2nd quarter. Advisory Services Network LLC now owns 160 shares of the medical research company’s stock valued at $50,000 after purchasing an additional 63 shares during the last quarter. Finally, CSat Investment Advisory L.P. bought a new stake in shares of Bio-Rad Laboratories in the 2nd quarter valued at approximately $132,000. 62.46% of the stock is owned by institutional investors and hedge funds.

Several research firms recently issued reports on BIO. ValuEngine cut Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research report on Tuesday. Barclays increased their target price on Bio-Rad Laboratories from $350.00 to $380.00 and gave the stock an “overweight” rating in a research report on Friday, August 2nd. They noted that the move was a valuation call. Finally, Goldman Sachs Group upgraded Bio-Rad Laboratories from a “buy” rating to a “conviction-buy” rating and set a $400.00 target price for the company in a research report on Tuesday, August 20th. Three equities research analysts have rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $378.33.

Shares of NYSE:BIO traded up $0.86 during trading on Friday, hitting $336.75. 70,332 shares of the company’s stock were exchanged, compared to its average volume of 200,153. The company has a debt-to-equity ratio of 0.11, a current ratio of 4.68 and a quick ratio of 3.36. Bio-Rad Laboratories has a 52-week low of $220.05 and a 52-week high of $345.50. The business’s 50-day simple moving average is $329.75 and its 200 day simple moving average is $309.28. The company has a market cap of $9.62 billion, a price-to-earnings ratio of 57.66, a PEG ratio of 2.99 and a beta of 1.18.

Bio-Rad Laboratories (NYSE:BIO) last released its quarterly earnings results on Thursday, August 1st. The medical research company reported $1.57 earnings per share for the quarter, beating the consensus estimate of $1.39 by $0.18. The business had revenue of $572.60 million during the quarter, compared to analysts’ expectations of $564.88 million. Bio-Rad Laboratories had a return on equity of 3.92% and a net margin of 39.32%. The firm’s revenue for the quarter was down .6% compared to the same quarter last year. During the same quarter last year, the business posted $1.64 EPS. On average, sell-side analysts anticipate that Bio-Rad Laboratories will post 7.19 EPS for the current fiscal year.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc develops, manufactures, and markets products and solutions for the life science research and clinical diagnostic markets in Europe, the Pacific Rim, the United States, and internationally. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components.

Further Reading: What is an economic bubble?

Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.